Oruka Therapeutics (ORKA) risk factors, FY2025 10-K

Oruka Therapeutics's FY2025 10-K, filed Mar 12, 2026, lists 53 risk factors in 7 groups. Against the prior year's 48: 7 new, 2 dropped, 20 substantially reworded.

Open ORKA in Gloom →
Oruka Therapeutics' chart, financials and news, free in your browser.Open ORKA in Gloom →
Risk factors listed
537 groups
New this year
7vs 48 last year
Dropped
2since the prior 10-K
Substantially reworded
20of those kept
Section length
23k wordsItem 1A

What the changes say

  • Oruka Therapeutics advanced its clinical pipeline, updating trial statuses for lead candidates ORKA-001 and ORKA-002 in psoriasis and other indications.
  • The company added new risk disclosures regarding foreign clinical trials, third-party manufacturing dependencies, and market opportunity forecast inaccuracies.
  • Registration of a massive stock resale for up to 39,425,806 shares heightened potential equity dilution and stock price volatility risks.

What changed since the prior 10-K

New

  • NewRisks Related to Our Reliance on Third Parties

    We currently rely on agreements with third parties to develop our product candidates. Our business could be negatively impacted if we are unable to maintain these arrangements or if these arrangements are not successful, for example, if such third parties fail to carry out their contractual duties

    We rely on third-party manufacturing partners who may fail to perform, forcing us to seek costly redundancies or switch providers.

  • NewRisks Related to Our Reliance on Third Parties

    Risks Related to Employee Matters, Managing Growth, Other Risks Related to Our Business, and Risks Related to Owning Our Common Stock

    Our estimates of market opportunity and growth forecasts for our product candidates may prove inaccurate.

  • NewRisks Related to Our Reliance on Third Parties

    Our business is dependent on key personnel, and we may be harmed if we cannot recruit and retain highly qualified personnel to successfully implement our business strategies

    Macroeconomic or geopolitical conditions could adversely affect our business and ability to recruit key personnel.

  • NewRisks Related to Clinical Development, Regulatory Approval and Commercialization

    The supply or quality of our clinical trial materials or other materials necessary to conduct clinical trials of our product candidates may be insufficient, unsafe or inadequate

    Clinical trials may face regulatory suspension, inadequate safety profiles, or insufficient trial material supplies.

  • NewRisks Related to Clinical Development, Regulatory Approval and Commercialization

    The number of subjects required for clinical trials of any product candidates may be larger than we anticipate, especially if regulatory bodies require completion of non-inferiority or superiority trials

    Clinical trials may require larger subject numbers than anticipated, and we may suffer from slow enrollment or high dropout rates.

  • NewRisks Related to Clinical Development, Regulatory Approval and Commercialization

    We may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and/or contract research organizations

    Trial sites or contract research organizations may fail to comply with regulations, causing development delays and increased costs.

  • NewRisks Related to Clinical Development, Regulatory Approval and Commercialization

    We are conducting, and may conduct in the future, clinical trials for programs at sites outside the United States, subjecting us to additional risks that may delay or adversely affect our product development timelines

    Conducting clinical trials outside the United States exposes us to differing regulatory standards and the risk that the FDA rejects foreign data.

Dropped

  • DroppedRisks Related to Clinical Development, Regulatory Approval and Commercialization

    Preliminary, “topline” or interim data from our clinical trials may change as more participant data becomes available and are subject to audit and verification procedures, and should be viewed with caution until the final data are available

  • DroppedRisks Related to Our Reliance on Third Parties

    We currently rely on our licensing arrangements with Paragon through the License Agreements for a substantial portion of our in-licenses

Reworded

  • 91% rewrittenRisks Related to Clinical Development, Regulatory Approval and Commercialization

    Our clinical development activities could be delayed or otherwise adversely affected if we encounter difficulties enrolling and maintaining participants in our current and future clinical trials. We depend on the successful completion of clinical trials for our product candidates

    Added specific consequences of participant enrollment and retention failures, noting they would result in significant delays and increased costs.

    Was: If we encounter difficulties enrolling participants in our current and future clinical trials, our clinical development activities could be delayed or otherwise adversely affected. We depend on the successful completion of clinical trials for our product candidates

  • 88% rewrittenRisks Related to Clinical Development, Regulatory Approval and Commercialization

    Certain of our programs may compete with our other programs, which could negatively impact our business and reduce our future revenue

    Updated indications from PsO to include HS and other I&I indications, noting competitive risks between concurrent internal trials.

  • 80% rewrittenRisks Related to Clinical Development, Regulatory Approval and Commercialization

    Our product candidates may fail in development or suffer delays. We depend on the successful initiation and completion of clinical trials for our product candidates to advance our product development plans

    Added a warning that preclinical and clinical data are susceptible to varying interpretations and frequently fail to gain marketing approval.

  • 72% rewrittenRisks Related to Owning Our Stock

    Future sales of shares by existing stockholders, or the anticipation of such events, could cause our stock price to decline

    Disclosed an October 2025 registration statement covering the resale of 39,425,806 shares of common stock, preferred stock, and warrants.

    Was: Future sales of shares by existing stockholders could cause our stock price to decline

  • 68% rewrittenRisks Related to Clinical Development, Regulatory Approval and Commercialization

    We are substantially dependent on the success of our two most advanced programs, ORKA-001 and ORKA-002, and our clinical trials of such programs may not be successful

    Updated clinical progress, noting the Phase 1 trial of ORKA-001 is fully enrolled and a Phase 2b dose-ranging trial commenced dosing.

  • 62% rewrittenRisks Related to Employee Matters, Managing Growth and Other Risks Related to Our Business

    We maintain our cash at financial institutions, often in balances that exceed federally-insured limits. The failure of financial institutions could adversely affect our ability to pay our operational expenses or make other payments

    Moved from General Risk Factors to standard risk format regarding bank deposits exceeding FDIC limits.

  • 60% rewrittenRisks Related to Government and Regulatory Matters

    Our product candidates for which we intend to seek approval as biologics may face competition sooner than anticipated

    No substantive textual changes made to the BPCIA biosimilar competition risk disclosure.

  • 58% rewrittenRisks Related to Clinical Development, Regulatory Approval and Commercialization

    Our approach to the discovery and development of our lead programs is unproven, and we may not be successful in our efforts to build a pipeline of programs with commercial value

    Explicitly named Paragon and Paruka Holding LLC in the discovery and option agreements for lead programs ORKA-001 and ORKA-002.

    Was: Our approach to the discovery and development of our programs is unproven, and we may not be successful in our efforts to build a pipeline of programs with commercial value

  • 50% rewrittenRisks Related to Our Financial Condition and Capital Requirements

    Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights

  • 45% rewrittenRisks Related to Employee Matters, Managing Growth and Other Risks Related to Our Business

    Our estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our business may not grow at similar rates, or at all

    Was: Our market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates that may not prove to be accurate. Even if the markets in which we compete meet our size estimates and growth forecasts, our business may not grow at similar rates, or at all

  • 44% rewrittenRisks Related to Clinical Development, Regulatory Approval and Commercialization

    We face competition from entities that have developed or may develop programs for the diseases addressed by our product candidates

  • 44% rewrittenRisks Related to Clinical Development, Regulatory Approval and Commercialization

    Any approved products resulting from our programs may not achieve adequate market acceptance among clinicians, patients, healthcare third-party payors and others in the medical community necessary for commercial success and we may not generate any future revenue from the sale or licensing of such products

  • 37% rewrittenRisks Related to Clinical Development, Regulatory Approval and Commercialization

    If we do not achieve our projected development goals in the time frames we announce or expect, the development and potential commercialization of our product candidates may be delayed and our expenses may increase and, as a result, our business may be materially harmed and our stock price may decline

    Was: If we do not achieve our projected development goals in the time frames we announce and expect, the development and potential commercialization of our product candidates may be delayed and our expenses may increase and, as a result, our business may be materially harmed and our stock price may decline

  • 35% rewrittenRisks Related to Employee Matters, Managing Growth and Other Risks Related to Our Business

    We may be subject to claims that we have wrongfully hired an employee from a competitor or that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties

  • 33% rewrittenRisks Related to Employee Matters, Managing Growth and Other Risks Related to Our Business

    Our business could be adversely affected by economic downturns, inflation, fluctuation in interest rates, natural disasters, public health crises, political crises, geopolitical events or other macroeconomic conditions, which could have a material and adverse effect on our results of operations and financial condition

  • 28% rewrittenRisks Related to Clinical Development, Regulatory Approval and Commercialization

    Any drug delivery device that we may use to deliver our product candidates may have its own regulatory, development, supply and other risks

  • 26% rewrittenRisks Related to Government and Regulatory Matters

    We may not be able to meet requirements for the chemistry, manufacturing, and control of our programs

  • 24% rewrittenRisks Related to Employee Matters, Managing Growth and Other Risks Related to Our Business

    Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties

  • 23% rewrittenRisks Related to Owning Our Stock

    The market price of our common stock has been, and may continue to be, volatile

  • 21% rewrittenRisks Related to Our Intellectual Property

    Patent terms may be inadequate to protect the competitive position of our product candidates for an adequate amount of time

All 53 risk factors

Headings as the filing states them, in filing order.

Risks Related to Our Reliance on Third Parties

  1. 01We currently rely on agreements with third parties to develop our product candidates. Our business could be negatively impacted if we are unable to maintain these arrangements or if these arrangements are not successful, for example, if such third parties fail to carry out their contractual dutiesNew
  2. 02Risks Related to Employee Matters, Managing Growth, Other Risks Related to Our Business, and Risks Related to Owning Our Common StockNew
  3. 03Our business is dependent on key personnel, and we may be harmed if we cannot recruit and retain highly qualified personnel to successfully implement our business strategiesNew

Risks Related to Our Financial Condition and Capital Requirements

  1. 04Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights50% rewritten

Risks Related to Clinical Development, Regulatory Approval and Commercialization

  1. 05We face competition from entities that have developed or may develop programs for the diseases addressed by our product candidates44% rewritten
  2. 06Our product candidates may fail in development or suffer delays. We depend on the successful initiation and completion of clinical trials for our product candidates to advance our product development plans80% rewritten
  3. 07The supply or quality of our clinical trial materials or other materials necessary to conduct clinical trials of our product candidates may be insufficient, unsafe or inadequateNew
  4. 08The number of subjects required for clinical trials of any product candidates may be larger than we anticipate, especially if regulatory bodies require completion of non-inferiority or superiority trialsNew
  5. 09We may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and/or contract research organizationsNew
  6. 10We are substantially dependent on the success of our two most advanced programs, ORKA-001 and ORKA-002, and our clinical trials of such programs may not be successful68% rewritten
  7. 11If we do not achieve our projected development goals in the time frames we announce or expect, the development and potential commercialization of our product candidates may be delayed and our expenses may increase and, as a result, our business may be materially harmed and our stock price may decline37% rewritten
  8. 12Any drug delivery device that we may use to deliver our product candidates may have its own regulatory, development, supply and other risks28% rewritten
  9. 13Our approach to the discovery and development of our lead programs is unproven, and we may not be successful in our efforts to build a pipeline of programs with commercial value58% rewritten
  10. 14Our clinical development activities could be delayed or otherwise adversely affected if we encounter difficulties enrolling and maintaining participants in our current and future clinical trials. We depend on the successful completion of clinical trials for our product candidates91% rewritten
  11. 15We may expend our limited resources to pursue a particular program and fail to capitalize on programs that may be more profitable or for which there is a greater likelihood of success
  12. 16Any approved products resulting from our programs may not achieve adequate market acceptance among clinicians, patients, healthcare third-party payors and others in the medical community necessary for commercial success and we may not generate any future revenue from the sale or licensing of such products44% rewritten
  13. 17Certain of our programs may compete with our other programs, which could negatively impact our business and reduce our future revenue88% rewritten
  14. 18We are conducting, and may conduct in the future, clinical trials for programs at sites outside the United States, subjecting us to additional risks that may delay or adversely affect our product development timelinesNew

Risks Related to Government and Regulatory Matters

  1. 19We may not be able to meet requirements for the chemistry, manufacturing, and control of our programs26% rewritten
  2. 20Our product candidates for which we intend to seek approval as biologics may face competition sooner than anticipated60% rewritten
  3. 21We may face difficulties from legislative or regulatory reform measures
  4. 22Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, including conflicts of interest rules, which could expose us to penalties
  5. 23Even if we are able to commercialize any product candidates, we may be subject to unfavorable pricing regulations and/or third-party coverage and reimbursement policies, and we may not be able to offer such product candidates at competitive prices, which could seriously harm our business
  6. 24Governments outside the United States tend to impose strict price controls, which may adversely affect our revenue, if any

Risks Related to Our Intellectual Property

  1. 25Our ability to obtain, maintain, and protect our patents and other proprietary rights is uncertain, exposing us to the possible loss of competitive advantage
  2. 26We may not be successful in obtaining or maintaining necessary rights to our programs through acquisitions and in-licenses
  3. 27We may be subject to patent infringement claims or may need to file claims to protect our intellectual property, which could result in substantial costs and liability and prevent us from commercializing our potential products
  4. 28Changes to patent laws in the U.S. and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products
  5. 29Obtaining and maintaining patent protection depends on compliance with various procedural, document submissions, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
  6. 30We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products
  7. 31We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property
  8. 32Patent terms may be inadequate to protect the competitive position of our product candidates for an adequate amount of time21% rewritten
  9. 33Our technology licensed from various third parties may be subject to retained rights

Risks Related to Employee Matters, Managing Growth and Other Risks Related to Our Business

  1. 34In order to successfully implement our plans and strategies, we will need to grow the size of our organization and we may experience difficulties in managing this growth
  2. 35We are highly dependent on our key personnel and anticipate hiring new key personnel. If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy
  3. 36We may be subject to claims that we have wrongfully hired an employee from a competitor or that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties35% rewritten
  4. 37Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties24% rewritten
  5. 38Our employees, independent contractors, consultants, advisors, commercial collaborators, principal investigators, CROs, CMOs, suppliers, and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
  6. 39Our hybrid-remote workforce may create additional risks for our information technology systems and data because our employees work remotely and utilize network connections, computers, and devices working at home, while in transit and in public locations
  7. 40If we fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business
  8. 41We may be subject to adverse U.S. legislative or regulatory tax changes that could negatively impact our financial condition
  9. 42We may acquire businesses or products, or form strategic alliances, in the future, and may not realize the benefits of such acquisitions
  10. 43We maintain our cash at financial institutions, often in balances that exceed federally-insured limits. The failure of financial institutions could adversely affect our ability to pay our operational expenses or make other payments62% rewritten
  11. 44Our estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our business may not grow at similar rates, or at all45% rewritten
  12. 45We may become exposed to costly and damaging product liability claims and our insurance may not cover all damages from such claims
  13. 46Litigation costs and the outcome of litigation could have a material adverse effect on our business
  14. 47Our business could be adversely affected by economic downturns, inflation, fluctuation in interest rates, natural disasters, public health crises, political crises, geopolitical events or other macroeconomic conditions, which could have a material and adverse effect on our results of operations and financial condition33% rewritten

Risks Related to Owning Our Stock

  1. 48The market price of our common stock has been, and may continue to be, volatile23% rewritten
  2. 49Our certificate of incorporation and bylaws, as well as provisions under Delaware law, could make an acquisition of the company more difficult and may prevent attempts by our stockholders to replace or remove management
  3. 50Future sales of shares by existing stockholders, or the anticipation of such events, could cause our stock price to decline72% rewritten
  4. 51We do not anticipate that we will pay any cash dividends in the foreseeable future
  5. 52Our executive officers, directors, and principal stockholders have the ability to control or significantly influence all matters submitted to our stockholders for approval
  6. 53If equity research analysts do not publish research or reports, or publish unfavorable research or reports about us, our business or our market, our stock price and trading volume could decline

Other Oruka Therapeutics 10-Ks

  • FY2024 10-K risk factors
    48 risks

    Oruka Therapeutics faces high clinical development risk, relying heavily on its two most advanced programs, ORKA-001 and ORKA-002, targeting PsO. The company depends heavily on external licensing partnerships like Paragon and must protect its intellectual property across a competitive biopharmaceutical landscape. Financial dilution, capital requirements, and strict regulatory and pricing hurdles also dominate its risk profile.

    Filed Mar 06, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.